This board like all public small message boards allow anyone to post. The list the supportive longs are developing have created an impact on the desperate FUDSTERS who apparently are so clueless they apparently don’t know the stages of list development. The first three items of the list were shared on the SI board as the top 3 reasons not to sell. Therefore, I will shed some light on the list development process; the first stage (the one we are currently working) is to brainstorm, next is to refine, and finally rank. The poster on the other board chose to ignore the first two phases of the process and presented the first run as the final result. Apparently knowledge is not a top priority of those wanting to see PTO fail. I will continue to develop the list but will do so on the two private boards.
This board like all public small message boards allow
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
OnTime's Bold Vision: Transforming Home Healthcare Admin
Changing the Game for Home Healthcare Every now and then, an idea rolls in that speaks to a real need, and OnTime's push to soften the burdens of the home healthcare industry might just be one of those. Built from grassroots experience, they're dropping efforts to modernize the back-end monotony so healthcare workers can zero in on, well, healthcare. A Nose-Dive into...
Continue Reading
Image Analysis Group Unveils DYNAMIKA V.7 for Clinical Trials
Introduction to DYNAMIKA V.7 by Image Analysis Group Image Analysis Group (IAG) has recently launched DYNAMIKA V.7, an advanced cloud platform tailored for clinical trial imaging. Following stringent audits and certifications, including SOC II Type I compliance and British Standards Institute (BSI) surveillance audit certification, this platform stands out in its field....
Continue Reading
Sanofi's Strategic Move to Enhance Adult Vaccination Pipeline
Sanofi Strengthens Its Vaccination Portfolio Sanofi SA (NASDAQ: SNY) has made a significant step in the healthcare sector by acquiring Dynavax Technologies Corporation (NASDAQ: DVAX) for approximately $2.2 billion. This acquisition, which involves a cash purchase price of $15.50 per share, signals Sanofi's commitment to enhancing its capabilities in the adult immunization...
Continue Reading
Miral Impact Fund: A New Era for Community and Environment
Introducing the Miral Impact Fund Miral has taken a significant step towards environmental stewardship and social responsibility by launching the Miral Impact Fund. This initiative, launched in partnership with the Authority of Social Contribution – Ma'an, aims to create a positive impact within communities by addressing pressing social issues while promoting...
Continue Reading
Class Action Update for Regeneron Pharmaceuticals Investors
Class Action Lawsuit Overview for Regeneron Pharmaceuticals Levi & Korsinsky, LLP has announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) investors should take note of a pending class action lawsuit concerning alleged securities fraud. Understanding the Class Action The lawsuit aims to recover losses for investors adversely affected by claims of fraud that...
Continue Reading